Goldman Sachs maintains "Buy" rating on IOVA due to positive Amtagvi data at ASCO.

From Yahoo Finance.: 2025-06-29 03:03:00

Goldman Sachs reaffirmed its “Buy” rating on Iovance Biotherapeutics (IOVA), one of the 10 best healthcare penny stocks to buy. The firm maintained a $34.00 price target for IOVA shares, based on positive Amtagvi data presented at the 2025 ASCO Annual Meeting. The FDA approved Amtagvi in 2024 for unresectable or metastatic melanoma.

The ASCO data highlighted Amtagvi’s safety profile and durability of responses in heavily pretreated advanced melanoma patients. Goldman Sachs emphasized the therapy’s successful US launch, consistent patient demand, and improved manufacturing quality metrics. IOVA is a biopharmaceutical company that develops cell therapies for solid tumors using a patient’s immune cells.

While IOVA offers investment potential, certain AI stocks may have greater upside with less downside risk. For those seeking undervalued AI stocks benefiting from tariffs and onshoring trends, consider exploring the best short-term AI stock. Explore Goldman Sachs’ Energy Stocks and the 10 Best AI Stocks to Buy for further investment opportunities.



Read more at Yahoo Finance.: Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data